Published in Bone on January 01, 2002
Novel therapy to reverse the cellular effects of bisphosphonates on primary human oral fibroblasts. J Oral Maxillofac Surg (2011) 1.50
Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res (2010) 1.39
Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer (2006) 1.22
Systemic treatment with strontium ranelate promotes tibial fracture healing in ovariectomized rats. Osteoporos Int (2009) 1.07
Enhancement of subchondral bone quality by alendronate administration for the reduction of cartilage degeneration in the early phase of experimental osteoarthritis. Clin Exp Med (2011) 0.88
Reduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate. Calcif Tissue Int (2011) 0.86
Cell replication in craniofacial periosteum: appositional vs. resorptive sites. J Anat (2011) 0.85
Osteonecrosis of jaws related to intravenous bisphosphonates: the experience of a Jordanian teaching hospital. Ann R Coll Surg Engl (2010) 0.84
Osteonecrosis of the jaws caused by bisphosphonates: evaluation of a new therapeutic approach using the Er:YAG laser. Lasers Med Sci (2009) 0.84
Alendronate reduces osteoclast precursors in osteoporosis. Osteoporos Int (2009) 0.82
Influence of bisphosphonate treatment on medullary macrophages and osteoclasts: an experimental study. Bone Marrow Res (2012) 0.80
Effect of bisphosphonates on orthodontic tooth movement-an update. J Clin Diagn Res (2015) 0.78
Effects of zoledronic acid and geranylgeraniol on the cellular behaviour and gene expression of primary human alveolar osteoblasts. Clin Oral Investig (2016) 0.78
Bisphosphonates inhibit cell functions of HUVECs, fibroblasts and osteogenic cells via inhibition of protein geranylgeranylation. Clin Oral Investig (2014) 0.78
Differences between the bisphosphonates for the prevention and treatment of osteoporosis. Ther Clin Risk Manag (2006) 0.77
Osteoconductive action of alendronate after implantation of beta tricalcium phosphate in rat adjuvant-induced arthritis. J Bone Miner Metab (2012) 0.76
Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists. J Bone Oncol (2013) 0.76
Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease. Wien Klin Wochenschr (2013) 0.76
Inositol hexakisphosphate inhibits osteoclastogenesis on RAW 264.7 cells and human primary osteoclasts. PLoS One (2012) 0.76
Genetics of the bone response to bisphosphonate treatments. Clin Cases Miner Bone Metab (2009) 0.76
Effect of alendronate on the mandible and long bones: an experimental study in vivo. Pediatr Res (2015) 0.75
Should all adjuvant breast cancer patients receive a bisphosphonate? Breast Cancer Res (2003) 0.75
Clodronate acts on human osteoclastic cell proliferation, differentiation and function in a bioreversible manner. Clin Cases Miner Bone Metab (2007) 0.75
Osteoporosis: the current status of mesenchymal stem cell-based therapy. Cell Mol Biol Lett (2016) 0.75
Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation. Endocrinology (2000) 2.51
Interpretation and use of FRAX in clinical practice. Osteoporos Int (2011) 2.43
Parathyroid venous sampling: anatomic considerations and results in 95 patients with primary hyperparathyroidism. Br J Radiol (1980) 2.29
Clinical risk factors as predictors of postmenopausal osteoporosis in general practice. Br J Gen Pract (2001) 1.73
Sclerostin: current knowledge and future perspectives. Calcif Tissue Int (2010) 1.71
1, 25-dihydroxycholecalciferol in the pathogenesis of the hypercalcaemia of sarcoidosis. Lancet (1979) 1.71
Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochem Biophys Res Commun (1989) 1.64
Exposure of KS483 cells to estrogen enhances osteogenesis and inhibits adipogenesis. J Bone Miner Res (2002) 1.49
[Prevalence of osteoporosis in postmenopausal women in family practice]. Ned Tijdschr Geneeskd (1999) 1.41
Epi- and metaphyseal changes in children caused by administration of bisphosphonates. Radiology (1992) 1.37
Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J (Clin Res Ed) (1987) 1.33
Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol (1993) 1.32
Studies of circulating parathyroid hormone in man using a homologous amino-terminal specific immunoradiometric assay. Clin Endocrinol (Oxf) (1980) 1.29
Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro. Ann Rheum Dis (2002) 1.24
Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone (2003) 1.24
Image-guided surgery in head and neck cancer: current practice and future directions of optical imaging. Head Neck (2011) 1.22
Interleukin-17: A new bone acting cytokine in vitro. J Bone Miner Res (1999) 1.20
Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum (1996) 1.19
Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol (2010) 1.19
Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) (1997) 1.17
Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner (1989) 1.15
Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Effects of mutant gene dosage on phenotype. J Clin Invest (1994) 1.13
Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis. J Clin Endocrinol Metab (1985) 1.12
Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships. Bone (1998) 1.11
Sclerostin in mineralized matrices and van Buchem disease. J Dent Res (2009) 1.11
End-organ resistance to 1,25-dihydroxycholecalciferol. Lancet (1980) 1.09
Reversible resistance to the renal action of parathyroid hormone in human vitamin D deficiency. Clin Sci (Lond) (1982) 1.09
Crystal agglomeration is a major element in calcium oxalate urinary stone formation. Kidney Int (1990) 1.06
Measurement of 1,25-dihydroxycholecalciferol in man by radioimmunoassay. Clin Endocrinol (Oxf) (1979) 1.05
Inducible production of nitric oxide in osteoblast-like cells and in fetal mouse bone explants is associated with suppression of osteoclastic bone resorption. J Clin Invest (1994) 1.04
Near-infrared fluorescence imaging in patients undergoing pancreaticoduodenectomy. Eur Surg Res (2011) 1.03
Mutations in the human Ca(2+)-sensing-receptor gene that cause familial hypocalciuric hypercalcemia. Am J Hum Genet (1995) 1.03
New insights into the role of vitamin D and calcium in osteoporosis management: an expert roundtable discussion. Curr Med Res Opin (2008) 1.02
Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res (1995) 1.00
Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study. J Rheumatol (1994) 1.00
The effects of dietary excesses in animal protein and in sodium on the composition and the crystallization kinetics of calcium oxalate monohydrate in urines of healthy men. J Clin Endocrinol Metab (1990) 1.00
A frame-shift mutation in the type I parathyroid hormone (PTH)/PTH-related peptide receptor causing Blomstrand lethal osteochondrodysplasia. J Clin Endocrinol Metab (1999) 1.00
Excessive crystal agglomeration with low citrate excretion in recurrent stone-formers. Lancet (1986) 1.00
Report on osteoporosis in the European Community: current status and recommendations for the future. Working Party from European Union Member States. Osteoporos Int (1998) 0.98
Intraoperative near-infrared fluorescence imaging of colorectal metastases targeting integrin α(v)β(3) expression in a syngeneic rat model. Eur J Surg Oncol (2011) 0.97
A potential role for the mast cell in the pathogenesis of idiopathic osteoporosis in men. Bone (2002) 0.97
Optical advances in skeletal imaging applied to bone metastases. Bone (2010) 0.97
Studies of hypoparathyroidism and pseudohypoparathyroidism. Q J Med (1978) 0.97
The prevalence of low bone mineral density in Dutch perimenopausal women: the Eindhoven perimenopausal osteoporosis study. Osteoporos Int (1998) 0.95
Bone metabolism in rheumatoid arthritis; relation to disease activity. Br J Rheumatol (1993) 0.92
Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis. Osteoporos Int (1999) 0.91
Serum osteocalcin in Paget's disease of bone: basal concentrations and response to bisphosphonate treatment. J Clin Endocrinol Metab (1987) 0.91
Bone morphogenetic proteins and their antagonists: the sclerostin paradigm. J Endocrinol Invest (2005) 0.91
Co-trimoxazole in chronic brucellosis: a two-year follow-up study. Br Med J (1975) 0.91
Inhibition of Gsk3β in cartilage induces osteoarthritic features through activation of the canonical Wnt signaling pathway. Osteoarthritis Cartilage (2011) 0.90
Spine radiographs to improve the identification of women at high risk for fractures. Osteoporos Int (2008) 0.90
Plasma nitrate+nitrite levels are regulated by ovarian steroids but do not correlate with trabecular bone mineral density in rats. J Endocrinol (1998) 0.90
Bone mineral density in ambulant, non-steroid treated female patients with rheumatoid arthritis. Clin Exp Rheumatol (1993) 0.90
Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate. J Clin Endocrinol Metab (1995) 0.89
Familial Paget's disease in The Netherlands: occurrence, identification of new mutations in the sequestosome 1 gene, and their clinical associations. Arthritis Rheum (2004) 0.89
Quantification of adherent and nonadherent cells cultured in 96-well plates using the supravital stain neutral red. Anal Biochem (1993) 0.89
In vivo quantification of the scattering properties of tissue using multi-diameter single fiber reflectance spectroscopy. Biomed Opt Express (2013) 0.89
Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone. Cancer Res (1996) 0.87
Characterization and evaluation of the artemis camera for fluorescence-guided cancer surgery. Mol Imaging Biol (2015) 0.87
Modulation of calcium oxalate monohydrate crystallization kinetics in vitro. Kidney Int (1988) 0.87
Expression of estrogen receptor alpha and beta in the epiphyseal plate of the rat. Bone (2002) 0.86
Ectopic production of 1,25-dihydroxyvitamin D by B-cell lymphoma as a cause of hypercalcemia. Cancer (1987) 0.86
Metabolites of vitamin D in human vitamin-D deficiency: effect of vitamin D3 or 1,25-dihydroxycholecalciferol. Lancet (1980) 0.86
Facial dysmorphia, parathyroid and thymic dysfunction in the father of a newborn with the DiGeorge complex. Eur J Pediatr (1989) 0.86
Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials. Int J Clin Pract (2010) 0.86
Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone (1998) 0.86
Novel mutations in the parathyroid hormone (PTH)/PTH-related peptide receptor type 1 causing Blomstrand osteochondrodysplasia types I and II. J Clin Endocrinol Metab (2006) 0.86
Towards a successful clinical implementation of fluorescence-guided surgery. Mol Imaging Biol (2014) 0.86
'In vivo' optical approaches to angiogenesis imaging. Angiogenesis (2010) 0.85
IL-1alpha, IL-1beta, IL-6, and TNF-alpha steady-state mRNA levels analyzed by reverse transcription-competitive PCR in bone marrow of gonadectomized mice. J Bone Miner Res (1998) 0.85
Regulation of parathyroid hormonelike protein production in cultured normal and malignant keratinocytes. J Invest Dermatol (1992) 0.84
1alpha-hydroxyvitamin D3 in the long-term management of hypoparathyroidism and pseudohypoparathyroidism. Clin Endocrinol (Oxf) (1977) 0.84
Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease. Pediatrics (1994) 0.84
Malignancy-associated hypercalcaemia: resolution of controversies over vitamin D metabolism by a pathophysiological approach to the syndrome. Clin Endocrinol (Oxf) (1994) 0.84
Development of homologous immunological assays for human parathyroid hormone. J Endocrinol (1980) 0.84
Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus. Eur J Endocrinol (2012) 0.84
Accelerated atherosclerosis and calcification in vein grafts: a study in APOE*3 Leiden transgenic mice. Circ Res (2002) 0.84
Optical imaging of cell death in traumatic brain injury using a heat shock protein-90 alkylator. Cell Death Dis (2013) 0.84
Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis. Bone (2009) 0.83
Usefulness of armspan and height comparison in detecting vertebral deformities in women. Osteoporos Int (1999) 0.83
Modulation of calcium oxalate monohydrate crystallization kinetics by urine of preterm neonates. Am J Kidney Dis (2001) 0.83
Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate). Eur J Pediatr (1997) 0.83
The role of 1,25-dihydroxyvitamin D in the maintenance of hypercalcemia in a patient with an ovarian carcinoma producing parathyroid hormone-related protein. Cancer (1991) 0.83
Long-term experience of alfacalcidol in renal osteodystrophy. Q J Med (1982) 0.83
Control of secretion of parathyroid hormone in secondary hyperparathyroidism. Clin Endocrinol (Oxf) (1982) 0.82
Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? Eur J Cancer (1996) 0.82
Normalized volume of interest selection and measurement of bone volume in microCT scans. Bone (2011) 0.82
Osteoclast formation together with interleukin-6 production in mouse long bones is increased by insulin-like growth factor-I. J Endocrinol (1992) 0.82
Effect of alendronate treatment on the osteoclastogenic potential of bone marrow cells in mice. Bone (1997) 0.82
Differential effects of aminosubstituted analogs of hydroxy bisphosphonates on the growth of Dictyostelium discoideum. J Bone Miner Res (1998) 0.81
Serum Dickkopf 1 levels in sclerostin deficiency. J Clin Endocrinol Metab (2013) 0.81